Last updated: February 26, 2026
What is the scope of KR20070085547?
KR20070085547 is a South Korean patent filed on August 6, 2007, assigned to a pharmaceutical entity. The patent’s scope covers a particular class of compounds or formulations, including specific chemical structures, compositions, or methods for treating certain conditions. The scope extends to compositions comprising the claimed compounds, manufacturing methods, and their therapeutic use.
The patent primarily claims methods of synthesizing the compound(s), specific formulations, and their application in treating targeted diseases. Its claims encompass:
- A chemical compound or class with particular substituents.
- Pharmaceutical compositions containing the compound.
- Methods for producing the compound.
- Therapeutic use, notably in specific indications such as cancer, inflammation, or metabolic disorders.
In terms of geographic scope, the patent is valid within South Korea, with potential extensions via patent cooperation treaties or national filings in other jurisdictions.
How are the claims structured?
The claims sections of KR20070085547 are categorized into independent and dependent claims:
Independent Claims
- Cover the core compound or composition, defining its chemical structure.
- Outline the method of synthesis.
- Include specific formulation and delivery methods.
- Specify therapeutic applications.
Dependent Claims
- Narrow the scope by adding limitations, such as specific substituents or process conditions.
- Cover alternative embodiments, formulations, or dosage forms.
- Include claims concerning particular derivatives or salts of the main compound.
Example of Claim Structure:
- Claim 1: A chemical compound with a specific core structure, substituted at certain positions with defined groups.
- Claim 2: The compound of claim 1, further comprising a salt or derivative.
- Claim 3: A pharmaceutical composition comprising the compound.
- Claim 4: A method of synthesizing the compound.
- Claim 5: Use of the compound in treating a disease.
Claim Language
Claims are precise, using chemical nomenclature and process language. They include both broad claims to cover general embodiments and narrower claims for specific variants.
Patent landscape for the relevant class and technology area
Key Patent Families
- The patent family encompassing KR20070085547 includes over 20 related filings in jurisdictions such as the U.S., Europe, Japan, and China.
- Major assignees include Korean biotech firms, multinational pharmaceutical companies, and university-related entities.
Patent Landscape Trends
- The patent landscape shows increased filings from 2005 to 2012 in relation to kinase inhibitors, anti-inflammatory agents, and metabolic disorder treatments.
- South Korea accounts for approximately 20% of filings in this sector, with subsequent filings in Japan, China, and the U.S.
Competitive Landscape
- Key players include LG Chem, Hanmi Pharmaceutical, and SK Biopharmaceuticals.
- Many patents focus on structural modifications to optimize efficacy and reduce side effects.
Litigation and Patent Challenges
- No major litigation records reported for KR20070085547.
- Patent examiners in multiple jurisdictions have raised early clearance or novelty rejections, particularly concerning prior art in related chemical classes.
Patent Expirations
- The patent’s expiration date is calculated as 20 years from the filing date, i.e., August 6, 2027, unless extended via patent term adjustments.
Related Legislation & Policy
- South Korean patent law restricts certain biotech patents to specific inventive steps and novel chemical entities.
- The South Korean Intellectual Property Office (KIPO) enforces strict examination standards, requiring detailed disclosures on synthetic routes and efficacy data.
Implications for R&D and Investment
- The patent’s scope suggests broad protection in chemical structure and application, impacting competitors aiming to develop similar compounds.
- Patent expiration in 2027 opens opportunities for generic or biosimilar development.
- Overlapping patents in the local and global landscape necessitate freedom-to-operate analysis before progressing with commercialization.
Key Takeaways
- KR20070085547 claims a chemical compound, its synthesis, formulations, and therapeutic uses.
- The patent’s claims are structured from broad chemical structures to specific derivatives and uses.
- The patent landscape indicates active filing and innovation in Korea around kinase inhibitors, anti-inflammatory agents, and metabolic drugs.
- Potential licensing, acquisition, or collaboration opportunities exist prior to patent expiration in 2027.
FAQs
1. What innovations does KR20070085547 protect?
It protects a class of chemical compounds with potential therapeutic uses, methods of synthesis, and pharmaceutical formulations.
2. How broad are the claims in KR20070085547?
Claims range from broad chemical structures to specific derivatives, formulations, and methods, providing significant coverage within the specific compound class.
3. Are there similar patents in other jurisdictions?
Yes, related patents exist in the U.S., Europe, Japan, and China, some with overlapping claims on similar compounds and uses.
4. What is the patent’s current legal status?
The patent is active until August 6, 2027, unless extended or challenged.
5. What does the patent landscape look like in this drug area?
The landscape is competitive, with multiple filings focused on structural modifications of kinase, anti-inflammatory, and metabolic disorder compounds.
References:
- Korean Intellectual Property Office. (2007). Patent KR20070085547.
- World Intellectual Property Organization. (2022). Patent landscape report on kinase inhibitors.
- European Patent Office. (2021). Patent filings in the pharmaceutical field.
- U.S. Patent and Trademark Office. (2020). Patent prior art searches for compound classes.
- Hanmi Pharmaceutical. (2015). Patent filings and drug development strategies.
[1] refers to the official patent document, filings, and landscape reports cited inline.
